Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hatch Flips Focus To NDI Guidance In McCain Steroid Bill Negotiations

This article was originally published in The Tan Sheet

Executive Summary

In a bit of legislative jiu-jitsu, congressional dietary supplement champions have redirected Sen. John McCain from sponsoring a bill that would put new burdens on industry to backing a provision that requires FDA publish a guidance stakeholders have been pushing for

You may also be interested in...



Herbalife Adds TCMs In JV: Health And Wellness Industry News Roundup

Herbalife adds traditional Chinese medicine to its portfolio as it reports 17.6% net income growth; PepsiCo's Naked Juice brand agrees to modify labeling in CSPI litigation; and House Health Subcommittee schedules hearing on improving sports' doping testing system.

N.Y. Supplement Marketing Restriction Bill Raises Specter Of Copycats

Stakeholders fear legislation proposed in New York to restrict sports supplement sales to consumers 18 and older and to require additional labeling could inspire copy-cats in other states. Trade groups say DSHEA already covers the proposed legislation’s goals.

N.Y. Supplement Marketing Restriction Bill Raises Specter Of Copycats

Stakeholders fear legislation proposed in New York to restrict sports supplement sales to consumers 18 and older and to require additional labeling could inspire copy-cats in other states. Trade groups say DSHEA already covers the proposed legislation’s goals.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel